(there's a sort of survey question near the end)
I've been on it for 3 months now. From starting dose of 50mcg for HU transition my dose last week was ~110.
-That evening I had high sensitivity to light, looking at the overhead kitchen light was nearly like looking at the sun. Even the white sink was painful to look at. This was just for that night.
-Has any member experienced any temporary (or long) change in this way?
--
Eyes and INF are known. See Euro warnings list at the end of this post. I fit the "other eye symptoms" in there. I've seen elsewhere (I think a UK label) an extreme warning on light sensitive on INF, but in combo with certain other conditions.
--
I made appt with my eye Dr. I also asked my Hem whether this result was normal, his one word answer was "no". So I worriedly moved the eye Dr appt up to today. I had an eye check last year for general eye pain, no issues then but we now had a reference point. Good news is my retina is still fine so I can keep the INF going.
A key INF eye hazard is lesions and "cotton wool spots". Dr also says these conditions are easily fixable these days. Most of these complications show up by 12 weeks on INF (from report below), I'm right there, as are many members on Bes. I have follow up eye appt in 3 months.
Eye Dr says the inflammation is likely the cause of the light sensitive, INF does make the body on fire by design. He had never heard of INF vs eyes, so he looked into it during my visit. He found this report (as is common it's for HepC):
--
ncbi.nlm.nih.gov/pmc/articl...
In here, this summary says it well (there's also a hidden bonus comparing PegIntron to PEG, I'll post separately)
<<Retinopathy was asymptomatic in most of the affected patients (7/9; 77.77%) and reversible, (I think it says the conditions improved while continuing INF) cotton wool spots was the major associated sign. Patients with older age, DM (diabetes) and or HTN, (blood pressure) and non-responders to antiviral therapy (this was for HepC) were associated with more severe retinopathy.>>
Some early reports from Japan have <<Higher frequencies are usually found in Japan where values of more than 50% are common>> I suspect doses were huge as it was early days for INF from my recollection.
--
-My take is esp if you have diabetes or hi blood pressure (even well controlled according to this study) you're at increased risk for retinopathy and esp if you notice any new eye issues, it may be good to consult an eye specialist. Age was another factor.
--
-I'm debating my next dose, Hem wants to keep it up. I've had plenty of flu like and GI since that 110mcg, but compared to malaise, I'll take those esp if they should get better over time as we see on the forum and Dr says.
(we're taking a rare vacation next week, so a lower dose for next one might allow me to enjoy it more)
--
-Another notable, I asked my Hem about weight vs INF dose, he said it's tolerance based, which is a sort of non-answer since then I ask myself is tolerance weight correlated? The report above has another hidden item on PegIntron if this area, it's dosed on weight while PEG is not. <<PEG IFN-α 2a was 180 mcg (subcutaneously) every week. The mean dose of PEG IFN-α 2b (PegIntron) was 1.5 mcg/kg (subcutaneously) every week.>> Besremi shares with Intron the -2b INF version.
That 180 PEG is very high for MPNs, so more eye issues in this study might be expected.
For weight/dose: I weigh 130lbs, US avg male is 200. So if INF were weight based as it is for Intron, my 110mcg Bes would require 170mcg for equivalence in the avg US male. Likewise a 270lb male (same weight diff the other way) would need 230mcg. Huge dose diffs if weight is relevant. Are some of us getting too much and others not enough on this basis?
-Have any members noticed any relation of your dose tolerance to weight? For example are some members who tolerate only lower dosing tending toward lighter weight than avg? (and vice versa)
--
As always comments welcome on what makes sense here and what doesn't.
--
Euro Warning:
ema.europa.eu/en/documents/...
<<Visual system
Severe eye disorders such as retinopathy, retinal haemorrhage, retinal exudates, retinal detachment and retinal artery or vein occlusion which may result in blindness have been observed rarely in patients treated with interferon alfa (see section 4.8). Patients should have eye examinations before and during
ropeginterferon alfa-2b therapy, specifically in those patients with retinopathy associated disease such as diabetes mellitus or hypertension. Any patient reporting a decrease or loss of vision or reporting other eye symptoms should have an immediate eye examination. Discontinuation of ropeginterferon
alfa-2b should be considered in patients who develop new or worsening eye disorders>>